ReviewWorld journal of hepatology2015
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations.World journal of clinical cases · 2023Article
- Incidental Hepatocellular Carcinoma after Liver Transplantation: Clinicopathologic Features and Prognosis.Medicina (Kaunas, Lithuania) · 2022Article
- DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation.World journal of hepatology · 2022Article
- Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma.Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2020Article
- Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series.Hepatoma research · 2020Article
- Low Serum Melatonin Levels Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma are Associated with Lower Survival after Liver Transplantation.International journal of molecular sciences · 2019Article
- mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.International journal of molecular sciences · 2019Article
- Treatment strategies for locally advanced hepatocellular carcinoma.Translational gastroenterology and hepatology · 2019Review
- Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria.Journal of hepatocellular carcinoma · 2019Review
- New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.World journal of gastroenterology · 2018Review
- Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survival.The Journal of international medical research · 2018Observational
- Article
- [Review and prospect of clinical study on liver transplantation of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Review
- Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact.PloS one · 2017Observational
- Liver transplantation for advanced hepatocellular carcinoma.Clinical and molecular hepatology · 2016Review
- Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma.International journal of molecular sciences · 2016Article
- Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway.Oncotarget · 2015Article
- LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation is the only therapeutic option which allows to treat both, the hepatocellular carcinoma and the underlying liver disease. Indeed, liver transplantation is considered the standard of care for a subset of patients with cirrhosis and hepatocellular carcinoma. However, tumour recurrence rates are as high as 20%, and once the recurrence is established the therapeutic options are scarce and with little impact on prognosis. Strategies to minimize tumour recurrence and thus to improve outcome may be classified into 3 groups: (1) An adequate selection of candidates for liver transplantation by using the Milan criteria; (2) An optimized management within waiting list including prioritization of patients at high risk of tumour progression, and the implementation of bridging therapies, particularly when the expected length within the waiting list is longer than 6 mo; and (3) Tailored immunosuppression comprising reduced exposure to calcineurin inhibitors, particularly early after liver transplantation, and the addition of mammalian target of rapamycin inhibitors. In the present manuscript the available scientific evidence supporting these strategies is comprehensively reviewed, and future directions are provided for novel research approaches, which may contribute to the final target: to cure more patients with hepatocellular carcinoma and with an improved long term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.